GoldenGolden
Advanced Search
Liquidia Technologies

Liquidia Technologies

Liquidia Technologies is a Durham, North Carolina-based nanotechnology company focused on development and commercialization of human therapeutics.

Liquidia Technologies is a company that maintains the mission of developing and changing how drugs and therapies are engineered. The company was founded in 2004, in Morrisville, North Carolina, United States.

The company has developed a proprietary technology named PRINT, which allows users to solve problems they may face in drug delivery and efficacy. The technology hold a scalable cGMP process that creates particle that can be applied to any therapeutic or point of administration.

PRINT allows for particle engineering platforms to provide control over drug particle size, shape, and chemical composition. This allows their users to selectively create their desired pharmacological effects such as time of drug release, amount of drug loading, route of administration, and novel storage and combination of products.

The platform allows for particle molding and allows users to deliver scalable processes that meet cGMP requirements. The technology is also a solution for semi-conductor markets as PRINT allows for the manufacturing of uniform particles at a commercially viable scale.

Timeline

January 19, 2010
Liquidia Technologies raises a $20,000,000 series C round from Canaan Partners, Morningside Group and New Enterprise Associates.
June 14, 2006
Liquidia Technologies raises a $6,000,000 series A round from Siemens Venture Capital.

Funding rounds

People

Name
Role
LinkedIn

Andrew Guo

Employee

Chris Concannon

Employee

Jon Harper

Employee

Michele Stone, Ph.D., PMP

Employee

Robert Lewis

Employee

Sajith

Employee

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
United Therapeutics Corporation
June 7, 2021
www.prnewswire.com:443
/PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it is pursuing additional claims for trade secret misappropriation against...
Mark Terry
November 23, 2020
BioSpace
The U.S. Food and Drug Administration (FDA) has a busy end of November planned, with numerous PDUFA dates to address. Here's a look at the upcoming week.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.